Home / Science / New Vaccine Turns Immune Memory Against Cancer
New Vaccine Turns Immune Memory Against Cancer
9 Jan
Summary
- Intratumoral vaccine molecule prevents cancer immune suppression.
- It redirects pre-existing immune memory to attack tumors.
- iVAC molecule degrades PD-L1 and delivers viral antigen.
Scientists have engineered a novel "intratumoral vaccine" molecule that offers a new strategy for cancer treatment. This innovative compound targets cancer cells directly, preventing them from suppressing the body's immune response. It simultaneously harnesses the immune system's existing memory to recognize and destroy malignant cells.
The dual-action molecule, named iVAC, works by degrading the PD-L1 protein on tumor cells, thereby releasing the immune system's brakes. Critically, it also delivers a viral antigen, marking the tumors with a foreign signature. This marking effectively redirects dormant "bystander T cells," which retain memory from prior infections, to identify and eliminate cancer cells.
Tests in mouse models and patient-derived tumor clusters have shown significant anti-tumor activity, validating the potential of this approach. Researchers are now developing this technology for future clinical trials, aiming to translate these promising findings into patient therapies.
